March 2024
1. CHEUNG D, Stucky CC, Fong ZV
   The rise of biliary tract cancers and next-generation population registries.
   Cancer. 2024 Mar 19. doi: 10.1002/cncr.35284.
   

   >> Share

   
   February 2024
2. CHOI WJ, Roberts S, Verma A, Razak F, et al
   Characterizing the burden of biliary tract cancers across 28 hospitals in Ontario, Canada.
   Cancer. 2024 Feb 15. doi: 10.1002/cncr.35249.
   

   >> Share

   
   
3. PATEL SP, Guadarrama E, Chae YK, Dennis MJ, et al
   SWOG 1609 cohort 48: anti-CTLA-4 and anti-PD-1 for advanced gallbladder cancer.
   Cancer. 2024 Feb 15. doi: 10.1002/cncr.35243.
   

   >> Share

   
   July 2023
4. CAI QY, Yang P, Yang XL, Zhang XH, et al
   The association of carbohydrate antigen 19-9 response with radiologic response and survival in intrahepatic cholangiocarcinoma: A prospective cohort study.
   Cancer. 2023 Jul 14. doi: 10.1002/cncr.34854.
   

   >> Share

   
   May 2023
5. JANKU F, Javle MM, Sen S, Pant S, et al
   A phase 1/2a safety, pharmacokinetics, and efficacy study of the novel nucleoside analog FF-10502-01 for the treatment of advanced solid tumors.
   Cancer. 2023;129:1537-1546.
   

   >> Share

   
   March 2023
6. KEARNEY JF, Weighill D, Yeh JJ
   Promise of bile circulating tumor DNA in biliary tract cancers.
   Cancer. 2023 Mar 18. doi: 10.1002/cncr.34715.
   

   >> Share

   
   
7. OHYAMA H, Hirotsu Y, Amemiya K, Miura Y, et al
   Comparison of genomic profiling of circulating tumor DNA in pancreaticobiliary malignancies in plasma and bile.
   Cancer. 2023 Mar 18. doi: 10.1002/cncr.34717.
   

   >> Share

   
   January 2023
8. HEMMINKI K, Sundquist K, Sundquist J, Forsti A, et al
   Autoimmune diseases as comorbidities for liver, gallbladder, and biliary duct cancers in Sweden.
   Cancer. 2023 Jan 30. doi: 10.1002/cncr.34663.
   

   >> Share

   
   
9. COFFMAN-D'ANNIBALE KL, Greten TF
   Top advances of the year: Hepatobiliary cancers.
   Cancer. 2023 Jan 24. doi: 10.1002/cncr.34652.
   

   >> Share

   
   
10. KLEIN O, Kee D, Nagrial A, Markman B, et al
    Is there a role for combined anti-PD-1/CTLA-4 checkpoint blockade in the management of advanced biliary tract cancers?
    Cancer. 2023 Jan 24. doi: 10.1002/cncr.34660.
    

    >> Share

    
    
11. SAHAI V, Zalupski MM
    Reply to "Is there a role for combined anti-PD-1/CTLA-4 checkpoint blockade in the management of advanced biliary tract cancers?".
    Cancer. 2023 Jan 24. doi: 10.1002/cncr.34659.
    

    >> Share

    
    
12. ZHANG J, Huang Q, Yang Y, Zhang J, et al
    A novel prognostic system combining carbonic anhydrase II and preoperative CA19-9 for intrahepatic cholangiocarcinoma after curative resection.
    Cancer. 2023 Jan 10. doi: 10.1002/cncr.34639.
    

    >> Share

    
    December 2022
13. SHRIDHAR R, Blinn P, Huston J, Meredith KL, et al
    Outcomes of adjuvant radiation therapy after chemotherapy in resected extrahepatic cholangiocarcinoma: A National Cancer Database analysis.
    Cancer. 2022 Dec 21. doi: 10.1002/cncr.34625.
    

    >> Share

    
    November 2022
14. ZHENG Y, Huang N, Kuang S, Zhang J, et al
    The clinicopathological significance and relapse predictive role of tumor microenvironment of intrahepatic cholangiocarcinoma after radical surgery.
    Cancer. 2022 Nov 26. doi: 10.1002/cncr.34552.
    

    >> Share

    
    
15. OHAEGBULAM KC, Koethe Y, Fung A, Mayo SC, et al
    The multidisciplinary management of cholangiocarcinoma.
    Cancer. 2022 Nov 16. doi: 10.1002/cncr.34541.
    

    >> Share

    
    August 2022
16. LEE YT, Singal AG, Lauzon M, Agopian VG, et al
    Disparities in curative treatments and outcomes for early stage intrahepatic cholangiocarcinoma in the United States.
    Cancer. 2022 Aug 23. doi: 10.1002/cncr.34436.
    

    >> Share

    
    July 2022
17. SAHAI V, Griffith KA, Beg MS, Shaib WL, et al
    A randomized phase 2 trial of nivolumab, gemcitabine, and cisplatin or nivolumab and ipilimumab in previously untreated advanced biliary cancer: BilT-01.
    Cancer. 2022 Jul 27. doi: 10.1002/cncr.34394.
    

    >> Share

    
    April 2022
18. DE B, Tran Cao HS, Vauthey JN, Manzar GS, et al
    Ablative liver radiotherapy for unresected intrahepatic cholangiocarcinoma: Patterns of care and survival in the United States.
    Cancer. 2022 Apr 13. doi: 10.1002/cncr.34223.
    

    >> Share

    
    November 2021
19. LEE TY, Bates SE, Abou-Alfa GK
    Equipoise, drug development, and biliary cancer.
    Cancer. 2021 Nov 24. doi: 10.1002/cncr.34020.
    

    >> Share

    
    August 2021
20. XU J, Bai Y, Sun H, Bai C, et al
    A single-arm, multicenter, open-label phase 2 trial of surufatinib in patients with unresectable or metastatic biliary tract cancer.
    Cancer. 2021 Aug 6. doi: 10.1002/cncr.33803.
    

    >> Share

    
    July 2021
21. SNYDER RA
    A noticeable absence.
    Cancer. 2021;127:2397-2398.
    

    >> Share

    
    March 2021
22. OUYANG G, Liu Q, Wu Y, Liu Z, et al
    The global, regional, and national burden of gallbladder and biliary tract cancer and its attributable risk factors in 195 countries and territories, 1990 to 2017: a systematic analysis for the Global Burden of Disease Study 2017.
    Cancer. 2021 Mar 22. doi: 10.1002/cncr.33476.
    

    >> Share

    
    December 2020
23. KAMARAJAH SK, Bednar F, Cho CS, Nathan H, et al
    Survival benefit with adjuvant radiotherapy after resection of distal cholangiocarcinoma: A propensity-matched National Cancer Database analysis.
    Cancer. 2020 Dec 15. doi: 10.1002/cncr.33356.
    

    >> Share

    
    
24. TAN ES, Cao B, Kim J, Al-Toubah TE, et al
    Phase 2 study of copanlisib in combination with gemcitabine and cisplatin in advanced biliary tract cancers.
    Cancer. 2020 Dec 8. doi: 10.1002/cncr.33364.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share